Mucormycosis in 2023: an update on pathogenesis and management

A Alqarihi, DP Kontoyiannis, AS Ibrahim - Frontiers in Cellular and …, 2023 - frontiersin.org
Mucormycosis (MCR) is an emerging and frequently lethal fungal infection caused by the
Mucorales family, with Rhizopus, Mucor, and Lichtheimia, accounting for> 90% of all cases …

Current treatments against mucormycosis and future directions

C Smith, SC Lee - PLoS Pathogens, 2022 - journals.plos.org
Mucormycosis (previously called zygomycosis) is a serious but rare fungal infection caused
by a group of fungi belonging to the order Mucorales. These molds exist throughout the …

New antifungal strategies: drug combination and co-delivery

P Zhu, Y Li, T Guo, S Liu, RJ Tancer, C Hu… - Advanced Drug Delivery …, 2023 - Elsevier
The growing occurrence of invasive fungal infections and the mounting rates of drug
resistance constitute a significant menace to human health. Antifungal drug combinations …

What is new in pulmonary mucormycosis?

F Danion, A Coste, C Le Hyaric, C Melenotte, F Lamoth… - Journal of Fungi, 2023 - mdpi.com
Mucormycosis is a rare but life-threatening fungal infection due to molds of the order
Mucorales. The incidence has been increasing over recent decades. Worldwide, pulmonary …

Salvage treatment for invasive aspergillosis and mucormycosis: challenges, recommendations and future considerations

M Egger, R Bellmann, R Krause, J Boyer… - Infection and drug …, 2023 - Taylor & Francis
Invasive mold diseases are devastating systemic infections which demand meticulous care
in selection, dosing, and therapy monitoring of antifungal drugs. Various circumstances …

[HTML][HTML] COVID-19-associated mucormycosis: a matter of concern amid the SARS-CoV-2 pandemic

P Chandley, P Subba, S Rohatgi - Vaccines, 2022 - mdpi.com
Mucormycosis is an invasive fungal infection caused by fungi belonging to order Mucorales.
Recently, with the increase in COVID-19 infections, mucormycosis infections have become a …

[HTML][HTML] Laboratory diagnosis of mucormycosis: Present perspective

MK Gupta, N Kumar, N Dhameja… - Journal of family …, 2022 - journals.lww.com
Upsurge in mucormycosis cases in the second wave of SARS CoV2 infection in India has
been reported. Uncontrolled diabetes is the major predisposing risk factor for these cases …

Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review

DS Meena, D Kumar, GK Bohra - Journal of Medical Mycology, 2023 - Elsevier
The emergence of Mucorales infections is an urgent global public health threat rapidly
disseminating during the current COVID-19 pandemic. Invasive mucormycosis carries …

Isavuconazole for the treatment of invasive mold disease in solid organ transplant recipients: a multicenter study on efficacy and safety in real-life clinical practice

M Fernández-Ruiz, M Bodro, IG Martín… - …, 2023 - journals.lww.com
Background. Isavuconazole has theoretical advantages over other mold-active triazoles for
the treatment of invasive aspergillosis and mucormycosis after solid organ transplantation …

[HTML][HTML] Isavuconazole and Amphotericin B Synergic Antifungal Activity: In Vitro Evaluation on Pulmonary Aspergillosis Molds Isolates

M Calvo, F Lauricella, AM Mellini, G Scalia, L Trovato - Antibiotics, 2024 - mdpi.com
Background/Objectives. Pulmonary aspergillosis is a severe respiratory infection caused by
Aspergillus spp., whose resistance profiles and invasive attitude complicate therapeutical …